Drugs / IDegLira
IDegLira
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 34 trials | ||||||
| Phase 3 | NCT05545800 | Sep 2022 → Jun 2024 | type 2 diabetes mellitus | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 3 | NCT03862716 | Apr 2019 → Jun 2022 | type 2 diabetes mellitus | Population Health Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT03737240 | Jan 2019 → Jul 2022 | type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
| Phase 3 | NCT01336023 | May 2011 → May 2012 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06408532 | Apr → Oct 2024 | type 2 diabetes mellitus | Peking University People's Hospital | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04196231 Comparator | Nov 2019 → Sep 2020 | type 2 diabetes mellitus | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
Press releases naming this drug 14 releases
| Date | Issuer | Release |
|---|---|---|
| 2016-09-02 | Novo Nordisk A/S | FDA forlænger registreringsprocessen for IDegLira med tre måneder novonordisk.com ↗ |
| 2016-09-02 | Novo Nordisk A/S | FDA extends regulatory review period for IDegLira by three months novonordisk.com ↗ |
| 2016-05-24 | Novo Nordisk A/S | FDA's rådgivende komite anbefaler godkendelse af IDegLira med stemmerne 16-0 novonordisk.com ↗ |
| 2016-05-24 | Novo Nordisk A/S | IDegLira receives positive 16-0 vote in favour of approval from FDA Advisory Committee novonordisk.com ↗ |
| 2016-05-20 | Novo Nordisk A/S | FDA offentliggør briefingmateriale forud for møde i rådgivende komite om IDegLira, en kombination af insulin degludec og liraglutid novonordisk.com ↗ |
| 2016-05-20 | Novo Nordisk A/S | FDA posts briefing materials prior to Advisory Committee meeting for IDegLira, a fixed combination product of insulin degludec and liraglutide novonordisk.com ↗ |
| 2014-09-18 | Novo Nordisk A/S | Xultophy® (IDegLira) approved in Europe novonordisk.com ↗ |
| 2014-09-18 | Novo Nordisk A/S | Xultophy® (IDegLira) godkendt i Europa novonordisk.com ↗ |
| 2014-07-25 | Novo Nordisk A/S | Novo Nordisk modtager positiv udtalelse om Xultophy® (IDegLira) fra de europæiske registreringsmyndigheder novonordisk.com ↗ |
| 2014-07-25 | Novo Nordisk A/S | Novo Nordisk receives positive opinion on Xultophy® (IDegLira) from the European regulatory authorities novonordisk.com ↗ |
| 2013-05-31 | Novo Nordisk A/S | Novo Nordisk indsender registreringsansøgning for IDegLira i EU til behandling af type 2-diabetes novonordisk.com ↗ |
| 2013-05-31 | Novo Nordisk A/S | Novo Nordisk files for regulatory approval of IDegLira in the EU for the treatment of type 2 diabetes novonordisk.com ↗ |
| 2012-12-19 | Novo Nordisk A/S | Det sidste fase 3a-studie for IDegLira afsluttet, og FIAsp godkendt til fase 3-udvikling novonordisk.com ↗ |
| 2012-12-19 | Novo Nordisk A/S | The final phase 3a trial for IDegLira completed, and FIAsp approved for phase 3 development novonordisk.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDegLira | “A fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone” PMID 25190523 ↗ Sep 2014 |
| Known as | insulin degludec/liraglutide | “Insulin degludec/liraglutide (IDegLira) is a novel fixed-ratio combination of the basal insulin insulin degludec (IDeg) and liraglutide, a glucagon-like peptide-1 analog.” PMID 25998481 ↗ Jul 20151“insulin degludec / liraglutide” NCT03862716 ↗ |
| Known as | Insulin Degludec/Liraglutide Combination | “Insulin Degludec/Liraglutide Combination (IDegLira)” NCT06408532 ↗ |
| Route | Subcutaneous | “Insulin degludec/liraglutide is injected subcutaneously (under the skin) once daily.” NCT01336023 ↗ |